GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

GeoVax Labs, Inc. announced that it has met the enrollment target for its Phase II clinical trial evaluating GEO-CM04S1 as a booster for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine